Skip to main content



reported earnings per share that broke even for the third quarter, beating the

First Call/Thomson Financial

estimate of a loss of 5 cents

The company lost 16 cents a share in the year-ago period.

The company said its third-quarter results include the operating results of

Signal Pharmaceuticals

. The merger of Signal and Celgene, which was completed on Aug. 31, was accounted for as a pooling of interests. Celgene's historical financial data has been restated to reflect the merger.